About us
ADC Programs
- Overview
- IKS03
- IKS014
- IKS04
- IKS073
- Discovery Programs
Platform Technologies
Partnering
News & Views
Contact

Search

News & Views

Latest News & Views

Filter:

All
Press Release

All
IKS014
IKS03
IKS04
Technology

All
2026
2025
2023
2022
2021
Archive

Reset

News & Views

Sorry, we couldn't find any results.

Sign up for more news

Thank you

Firstname *required field

Last name *required field

Email address *required field

I confirm that I have read the data protection and Privacy Policy and that I agree to the processing of my personal data

Iksuda Therapeutics is creating class leading ADCs with enhanced tumor specificity for hard-to-treat cancers. We are building a pipeline of ADC programs centered around tumor-selective delivery of the most relevant payload for any given target & tumor indication. Our ADC design principles are enabled by multiple in-house platforms, including novel linkers, numerous payload series and stable bioconjugation platforms

About us
ADC Design Principles
Partnerships
News & Views
Contact

© Copyright 2026 Iksuda

Privacy Policy
Cookie Policy
Terms of Use
Accessibility

Designed and built by SampsonMay